Stifel analyst David Grossman lowered the firm’s price target on DocGo (DCGO) to $4 from $5.50 and keeps a Buy rating on the shares. Q1 revenue and non-GAAP EBITDA missed expectations and the company “materially lowered” 2025 guidance, notes the analyst, who points out that the revised range fell “well below” the firm’s estimates even though they were “significantly below consensus.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCGO:
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- DocGo downgraded to Neutral from Buy at BTIG
- DocGo: Buy Rating Affirmed Amid Temporary Government Sector Challenges and Promising Growth in Other Segments
- DocGo Inc. Reports Q1 2025 Earnings Amid Strategic Shift
- DocGo reports Q1 EPS (9c) consensus 3c